Exodus Point Capital Management, LP Prothena Corp Public LTD CO Transaction History

Exodus Point Capital Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$19.54 - $26.15 $920,470 - $1.23 Million	47,107 New	47,107 $972,000
Q3 2023 Nov 09, 2023	BUY	$47.3 - $70.6 $2.88 Million - $4.3 Million	60,853 New	60,853 $2.94 Million
Q3 2022 Nov 10, 2022	SELL	$25.16 - $60.63 $1.06 Million - $2.56 Million	-42,213 Closed	0 $0
Q2 2022 Aug 19, 2022	SELL	$22.73 - $39.98 $647,554 - $1.14 Million	-28,489 Reduced 40.29%	42,213 $1.15 Million
Q1 2022 May 13, 2022	SELL	$30.27 - $49.22 $2.79 Million - $4.54 Million	-92,156 Reduced 56.59%	70,702 $2.59 Million
Q4 2021 Feb 11, 2022	BUY	$42.11 - $73.26 $6.86 Million - $11.9 Million	162,858 New	162,858 $8.05 Million
Q1 2021 May 17, 2021	SELL	$11.0 - $28.24 $172,612 - $443,142	-15,692 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$10.12 - $13.94 $79,016 - $108,843	-7,808 Reduced 33.23%	15,692 $188,000
Q3 2020 Nov 16, 2020	BUY	$9.93 - $13.47 $109,349 - $148,331	11,012 Added 88.18%	23,500 $235,000
Q2 2020 Aug 14, 2020	BUY	$9.56 - $12.51 $119,385 - $156,224	12,488 New	12,488 $131,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $714M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.